

09-J0000-66

Original Effective Date: 11/15/06

Reviewed:10/08/25

Revised: **06/01/26**

Subject: Bevacizumab (Avastin), bevacizumab-awwb (Mvasi), bevacizumab-bvzr (Zirabev), and bevacizumab-maly (Alymsys), bevacizumab-nwgd (Jobevne), bevacizumab-tnjn (Avzivi), and bevacizumab-adcd (Vegzelma) Injection

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Dosage/ Administration	Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions
Related Guidelines	Other	References	Updates		

DESCRIPTION:

Bevacizumab (Avastin) is a humanized monoclonal antibody that inhibits the binding of vascular endothelial growth factor (VEGF) to its receptors, VEGFR-1 and VEGFR-2. This action neutralizes the biological activity of VEGF ultimately inhibiting the formation of new tumor vessels. Alone, bevacizumab is not directly cytotoxic; as such it is commonly used in combination with traditional cytotoxic treatment modalities including chemotherapy, radiation therapy, and hormonal therapy in the treatment of cancer.

Bevacizumab was initially approved by the US Food and Drug Administration (FDA) as a first-line treatment option for metastatic colorectal cancer in combination with 5-fluorouracil (5-FU). The initial approval in colorectal cancer was expanded to include second-line therapy. Bevacizumab, in combination with carboplatin and paclitaxel, was also FDA-approved for first-line treatment of locally advanced, recurrent, or metastatic non-squamous, non-small cell lung cancer (NSCLC). Bevacizumab has also been approved in combination with paclitaxel for use in persons who had not previously received chemotherapy for metastatic HER2-negative breast cancer; however, in 2011, the FDA removed approval for the breast cancer indication after review of clinical data indicated that the drug did not prolong overall survival in breast cancer patients or provide sufficient benefit in slowing disease progression to outweigh the significant risk. Bevacizumab has also been approved for the treatment of glioblastoma in persons with disease that has progressed on prior therapy, metastatic renal cell carcinoma in combination with interferon-alfa, cervical cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in combination with chemotherapy, and hepatocellular carcinoma in combination with atezolizumab.

Current National Comprehensive Cancer Network (NCCN) guidelines support the use of bevacizumab in a variety of cancers including ampullary cancer, cervical cancer, CNS cancer, colorectal cancer, hepatocellular carcinoma, kidney cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, small bowel adenocarcinoma, soft tissue sarcoma, uterine, vaginal, and vulvar cancer. Bevacizumab-awwb

(Mvasi), bevacizumab-bvzr (Zirabev), bevacizumab-maly (Alymsys), bevacizumab-nwgd (Jobevne), bevacizumab-tnjin (Avzivi), and bevacizumab-adcd (Vegzelma) are FDA-approved biosimilars of bevacizumab.

POSITION STATEMENT:

Drug Waste Reduction: Additional medical necessity criteria for dose optimization may apply depending on the requested dose and member's benefit. Refer to Medical Coverage Guideline [Drug Waste Reduction, 09-J5000-54](#).

NOTE: For ophthalmic indications, please refer to MCG # 09-J1000-78, Vascular Endothelial Growth Factor Inhibitors of Ocular Neovascularization.

- I. Initiation of bevacizumab (Avastin®), bevacizumab-awwb (Mvasi), bevacizumab-bvzr (Zirabev), bevacizumab-maly (Alymsys), bevacizumab-nwgd (Jobevne), bevacizumab-tnjin (Avzivi), or bevacizumab-adcd (Vegzelma) **meets the definition of medical necessity** when ALL of the following are met:
 1. When used to treat an indication listed in Table 1 and **ALL** of the indication-specific criteria are met
 2. When the dose does not exceed either of the following:
 - a. 10 mg/kg every 2 weeks
 - b. 15 mg/kg every 3 weeks
 3. For Avastin, Alymsys, Avzivi, Jobevne, or Vegzelma requests only, the member has an inadequate response, contraindication, or intolerance to bevacizumab-awwb (Mvasi) OR bevacizumab-bvzr (Zirabev)[†] - documentation must be submitted

Table 1

Indications and Specific Criteria	
Indication	Criteria
Ampullary Cancer	<p>BOTH of the following:</p> <ol style="list-style-type: none"> 1. Member has unresectable, advanced, or metastatic intestinal type disease 2. When used as a component of ONE of the following regimens: <ol style="list-style-type: none"> a. FOLFOX (fluorouracil, leucovorin, oxaliplatin) b. CapeOX (capecitabine and oxaliplatin) c. FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) d. Capecitabine e. Fluorouracil and leucovorin f. FOLFIRI (fluorouracil, leucovorin, irinotecan)
Cervical Cancer	<p>BOTH of the following:</p> <ol style="list-style-type: none"> 1. Member's disease is persistent, recurrent, or metastatic 2. ONE of the following: <ol style="list-style-type: none"> a. When used in combination with paclitaxel and ONE of the following: <ol style="list-style-type: none"> i. cisplatin ii. carboplatin iii. topotecan b. When used in combination with chemotherapy and pembrolizumab c. When used in combination with chemotherapy and atezolizumab

	d. When used as a single agent as second-line or subsequent therapy
CNS Cancer	<p>When used for treatment of ONE of the following</p> <ol style="list-style-type: none"> 1. Recurrent or progressive disease as a single agent for ONE of the following: <ol style="list-style-type: none"> a. Glioblastoma b. High grade glioma c. Intracranial and/or spinal ependymoma (excludes subependymoma) d. Meningiomas e. WHO Grade 3 or 4 IDH-mutant Astrocytoma f. WHO Grade 3 Oligodendroglioma (IDH-mutant, 1p19q codeleted) 2. Recurrent or progressive disease in combination with carmustine, lomustine, or temozolomide (with or without irinotecan) for ONE of the following: <ol style="list-style-type: none"> a. Glioblastoma b. High grade glioma c. Medulloblastoma d. WHO Grade 3 or 4 IDH-mutant Astrocytoma e. WHO Grade 3 Oligodendroglioma (IDH-mutant, 1p19q codeleted) 3. For recurrent or progressive disease in combination with temozolomide and irinotecan for medulloblastoma 4. For symptoms of radiation necrosis, poorly controlled vasogenic edema or mass effect 5. For Neurofibromatosis type 2 vestibular schwannomas as a single agent 6. For pediatric diffuse high-grade gliomas or pediatric medulloblastoma
Colon and Rectal Cancer (also includes anal adenocarcinoma and appendiceal adenocarcinoma)	<p>BOTH of the following:</p> <ol style="list-style-type: none"> 1. Member has ONE of the following: <ol style="list-style-type: none"> a. Metastatic disease b. Unresectable disease c. Advanced disease d. Medically inoperable disease 2. ONE of the following: <ol style="list-style-type: none"> a. When used as a component of one of the following regimens: <ol style="list-style-type: none"> i. FOLFOX (fluorouracil, leucovorin, oxaliplatin) ii. FOLFIRI (fluorouracil, leucovorin, irinotecan) iii. CapeOX (capecitabine and oxaliplatin) iv. FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) v. Irinotecan vi. Irinotecan and oxaliplatin vii. Capecitabine viii. 5-FU/LV (fluorouracil and leucovorin) b. When used as subsequent therapy in combination with trifluridine/tipiracil (Lonsurf) if disease progression on fluoropyrimidine-, oxaliplatin-, and irinotecan-based therapy
Hepatocellular carcinoma	<p>When ALL of the following are met:</p> <ol style="list-style-type: none"> 1. When used in combination with atezolizumab 2. ONE of the following: <ol style="list-style-type: none"> a. Unresectable disease and is not a candidate for transplant

	<ul style="list-style-type: none"> b. Metastatic disease c. Inoperable due to performance status or comorbidities d. At high risk of recurrence
Hereditary hemorrhagic telangiectasia	<p>When the member has ONE of the following:</p> <ul style="list-style-type: none"> 1. Received red blood cell transfusions for HHT-associated bleeding 2. Liver vascular malformations (LVMs) and symptomatic high-output cardiac failure
Kidney Cancer	<p>BOTH of the following:</p> <ul style="list-style-type: none"> 1. Member has relapsed or stage IV disease 2. ANY of the following: <ul style="list-style-type: none"> a. When used in combination with interferon alfa-2b b. When used in combination with everolimus (Afinitor) in persons with non-clear cell histology c. When used in combination with erlotinib (Tarceva) in persons with advanced papillary renal cell carcinoma including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
Mesothelioma	<p>ONE of the following:</p> <ul style="list-style-type: none"> 1. Pleural mesothelioma <ul style="list-style-type: none"> a. When used in combination with pemetrexed and cisplatin or carboplatin on day 1 every 3 weeks for 6 cycles followed by single-agent maintenance therapy 2. Peritoneal mesothelioma, pericardial mesothelioma, and tunica vaginalis testis mesothelioma <ul style="list-style-type: none"> a. When used in combination with pemetrexed and cisplatin or carboplatin on day 1 every 3 weeks for 6 cycles followed by single-agent maintenance therapy b. When used in combination with atezolizumab as subsequent therapy if not previously treated with immune checkpoint inhibitors
Non-small cell lung cancer (NSCLC)	<p>ALL of the following:</p> <ul style="list-style-type: none"> 1. Member's NSCLC histology is non-squamous cell 2. Member's disease is advanced, recurrent, or metastatic 3. ONE of the following: <ul style="list-style-type: none"> a. Used in combination with pemetrexed and cisplatin b. Used in combination with pemetrexed and carboplatin c. Used in combination with paclitaxel and carboplatin d. Used in combination with paclitaxel, carboplatin, and atezolizumab e. Used in combination with nab-paclitaxel and carboplatin when member has a documented hypersensitivity to conventional paclitaxel or docetaxel f. Used in combination with atezolizumab for maintenance therapy if previously used as part of first-line atezolizumab/carboplatin/paclitaxel/bevacizumab g. Used in combination with pemetrexed for maintenance therapy if previously used with a first-line pemetrexed/platinum chemotherapy regimen h. Used in combination with erlotinib i. Single agent maintenance therapy
Ovarian Cancer [includes epithelial, fallopian tube, primary peritoneal, and less common ovarian histologies (carcinosarcoma or	<p>ONE of the following:</p> <ul style="list-style-type: none"> 1. For treatment of recurrent or persistent disease as a single agent or in combination with ONE of the following: <ul style="list-style-type: none"> a. cyclophosphamide b. cyclophosphamide and pembrolizumab c. gemcitabine

<p>malignant mixed Mullerian tumors, clear cell carcinoma, mucinous carcinoma, serous carcinoma, endometrioid carcinoma, borderline epithelial tumors with invasive implants, malignant sex cord-stromal tumors)]</p>	<ul style="list-style-type: none"> d. gemcitabine and carboplatin e. liposomal doxorubicin and carboplatin f. liposomal doxorubicin g. mirvetuximab soravtansine-gynx h. paclitaxel i. paclitaxel and carboplatin j. topotecan <ul style="list-style-type: none"> 2. When used in combination with paclitaxel and carboplatin 3. When used in combination with docetaxel and carboplatin 4. When used in combination with docetaxel and oxaliplatin 5. When used as single agent maintenance therapy 6. When used in combination with olaparib or niraparib for maintenance therapy after complete or partial remission with primary treatment containing bevacizumab
<p>Radiation necrosis of the brain</p>	<p>When the member is symptomatic</p>
<p>Small Bowel Adenocarcinoma</p>	<p>BOTH of the following:</p> <ul style="list-style-type: none"> 1. Member has advanced or metastatic disease 2. When used as a component of ONE of the following regimens: <ul style="list-style-type: none"> a. FOLFOX (fluorouracil, leucovorin, oxaliplatin) b. FOLFIRI (fluorouracil, leucovorin, irinotecan) c. CapeOX (capecitabine and oxaliplatin) d. FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) e. Capecitabine f. 5-FU/LV (fluorouracil and leucovorin)
<p>Soft-tissue sarcoma (STS)</p>	<p>ONE of the following:</p> <ul style="list-style-type: none"> 1. Used as a single agent for angiosarcoma 2. Used in combination with temozolomide (Temodar) for treatment of solitary fibrous tumor
<p>Uterine Neoplasm</p>	<p>When used for ONE of the following:</p> <ul style="list-style-type: none"> 1. Used as a single agent in members who have progressed on prior cytotoxic chemotherapy 2. Used in combination with carboplatin and paclitaxel 3. Used as single agent maintenance therapy
<p>Vaginal cancer</p>	<p>When used as a single agent or with ONE of the following:</p> <ul style="list-style-type: none"> 1. carboplatin and paclitaxel 2. cisplatin and paclitaxel 3. pembrolizumab, paclitaxel and carboplatin 4. pembrolizumab, paclitaxel and cisplatin 5. topotecan and paclitaxel
<p>Vulvar cancer</p>	<p>BOTH of the following:</p> <ul style="list-style-type: none"> 1. Member has advanced, unresectable, recurrent or metastatic disease 2. Will be used in combination with paclitaxel and either cisplatin or carboplatin
<p>Other FDA-approved or NCCN supported diagnosis (not previously listed above)</p>	<p>When ONE of the following are met:</p> <ul style="list-style-type: none"> 1. Member is diagnosed with a condition that is consistent with an indication listed in the product's FDA-approved prescribing information (or package insert) AND member meets any additional requirements listed in the "Indications and Usage" section of the FDA-approved prescribing information (or package insert) 2. Indication AND usage is recognized in NCCN Drugs and Biologics Compendium as a Category 1 or 2A recommendation

CNS, central nervous system

Approval Duration: 180 days

- II. Continuation of bevacizumab (Avastin®), bevacizumab-trjnj (Avzivi), bevacizumab-awwb (Mvasi), bevacizumab-bvzr (Zirabev), bevacizumab-maly (Alymsys), bevacizumab-nwgd (Jobevne), or bevacizumab-adcd (Vegzelma) **meets the definition of medical necessity** for the indications in Table 1 above when **ALL** of the following criteria are met:
- The member has been previously approved by Florida Blue or another healthplan in the past 2 years, **OR** the member has previously met all indication-specific criteria
 - The dose does not exceed **EITHER** of the following:
 - 10 mg/kg every 2 weeks
 - 15 mg/kg every 3 weeks

Approval duration: 1 year

† Step therapy does not apply for bevacizumab (Avastin), bevacizumab-maly (Alymsys), bevacizumab-trjnj (Avzivi), or Vegzelma if a prior health plan paid for the medication - documentation of a paid claim within the past 90 days must be submitted

DOSAGE/ADMINISTRATION:

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS. PROVIDERS SHOULD REFER TO THE MANUFACTURER'S FULL PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE MAKING ANY CLINICAL DECISIONS REGARDING ITS USAGE.

FDA-approved: the FDA-approved indications and dosing for bevacizumab are identified in Table 2. Bevacizumab should be administered as an intravenous (IV) infusion. The first infusion should be administered over 90 minutes. If the first infusion is tolerated, the second infusion can be administered over 60 minutes; subsequent infusions can be administered over 30 minutes if the second infusion over 60 minutes is tolerated. See prescribing information for biosimilar products bevacizumab-awwb and bevacizumab-bvzr.

Table 2

FDA-approved indications and dosing for bevacizumab	
Indication	Dosage Regimen†
Metastatic Colorectal Cancer	5 mg/kg every 2 weeks with bolus irinotecan/5-FU/leucovorin
	10 mg/kg every 2 weeks with 5-FU/leucovorin/oxaliplatin
	5 mg/kg every 2 weeks or 7.5 mg every 3 weeks with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy after progression on first line bevacizumab containing regimen
Non-squamous NSCLC	15 mg/kg every 3 weeks with carboplatin/paclitaxel
Recurrent Glioblastoma	10 mg/kg every 2 weeks
Metastatic RCC	10 mg/kg every 2 weeks with interferon alfa
Persistent, recurrent, or metastatic carcinoma of the cervix	15 mg/kg IV every 3 weeks with paclitaxel/cisplatin or paclitaxel/topotecan
Stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection	15 mg/kg IV every 3 weeks with carboplatin or paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles

Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer	10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin or weekly topotecan
	15 mg/kg IV every 3 weeks with topotecan given every 3 weeks
Platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer	15 mg/kg IV every 3 weeks with carboplatin/paclitaxel for 6 to 8 cycles followed by 15 mg/kg every 3 weeks as a single agent
	15 mg/kg IV every 3 weeks with carboplatin/gemcitabine for 6 to 10 cycles followed by 15 mg/kg every 3 weeks as a single agent
Hepatocellular carcinoma	15 mg/kg IV every 3 weeks with atezolizumab given every 3 weeks
†Bevacizumab should be administered as an intravenous (IV) infusion; do not administer as an IV bolus or push. NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.	

Dose modifications: there are no recommended dose reductions for bevacizumab. Bevacizumab should be discontinued in the following clinical situations:

- Gastrointestinal perforations (gastrointestinal perforations, fistula formation in the gastrointestinal tract, intra-abdominal abscess), fistula formation involving an internal organ
- Wound dehiscence and wound healing complications requiring medical intervention, necrotizing fasciitis
- Serious hemorrhage (i.e., requiring medical intervention)
- Severe arterial thromboembolic events
- Life-threatening (Grade 4) venous thromboembolic events, including pulmonary embolism
- Hypertensive crisis or hypertensive encephalopathy
- Posterior Reversible Encephalopathy syndrome (PRES)
- Nephrotic syndrome
- Congestive Heart Failure

Bevacizumab should be temporarily suspended in the following clinical situations:

- At least 4 weeks prior to elective surgery
- Severe hypertension not controlled with medical management
- Moderate to severe proteinuria pending further evaluation
- Severe infusion reactions

Drug Availability: Bevacizumab, bevacizumab-adcd, bevacizumab-awwb, bevacizumab-bvzr, and bevacizumab-maly are all supplied as a 100 mg/4 mL single-use vial and a 400 mg/16 mL single use vial.

PRECAUTIONS:

- Gastrointestinal Perforation or fistula: Discontinue bevacizumab if perforation or fistula formation occurs.
- Surgery and Wound Healing Complications: Discontinue in persons with wound dehiscence. Discontinue at least 28 days prior to elective surgery. Do not initiate bevacizumab for at least 28 days after surgery and until the surgical wound is fully healed.
- Hemorrhage: Severe or fatal hemorrhage, hemoptysis, gastrointestinal bleeding, CNS hemorrhage, and vaginal bleeding are increased in bevacizumab- treated individuals. Do not administer bevacizumab to individuals with serious hemorrhage or recent hemoptysis. Discontinue for Grade 3-4 hemorrhage.

- Arterial Thromboembolic Events (ATE) (e.g., myocardial infarction, cerebral infarction): Discontinue bevacizumab for severe ATE.
- Venous Thromboembolic Events: Discontinue bevacizumab for life-threatening events.
- Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend bevacizumab if not medically controlled. Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy.
- Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue bevacizumab.
- Renal injury and Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome. Temporarily suspend bevacizumab for moderate proteinuria.
- Infusion Reactions: Stop for severe infusion reactions.
- Embryo-fetal toxicity: Advise females of potential risk to a fetus and the need for use of effective contraception.
- Ovarian Failure: Inform females of reproductive potential of the risk of ovarian failure with bevacizumab.
- Congestive Heart Failure (CHF): discontinue if CHF occurs.

BILLING/CODING INFORMATION:

The following codes may be used to describe:

HCPCS Coding:

J9035	Injection, bevacizumab, 10 mg
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
Q5118	Injection, bevacizumab-bvzr, biosimilar (Zirabev), 10 mg
Q5126	Injection, bevacizumab-maly, biosimilar, (Alymsys), 10 mg
Q5129	Injection, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg
Q5160	Injection, bevacizumab-nwgd (Jobevne), biosimilar, 10 mg

ICD-10 Diagnosis Codes That Support Medical Necessity:

C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0 – C18.9	Malignant neoplasm of colon
C19 – C20	Malignant neoplasm of rectosigmoid junction and rectum
C21.0 – C21.8	Malignant neoplasm of anus and anal canal
C22.0	Liver cell carcinoma
C22.3	Angiosarcoma of liver
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C24.1	Malignant neoplasm of ampulla of Vater
C33 – C34.92	Malignant neoplasm of trachea, bronchus and lung
C38.4	Malignant neoplasm of pleura
C45.0 – C45.9	Mesothelioma of pleura, peritoneum, pericardium, and other sites
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C48.0	Malignant neoplasm of retroperitoneum
C48.1	Malignant neoplasm of specified parts of peritoneum

C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.0 – C49.9	Malignant neoplasm of connective and soft tissue
C51.0 – C51.9	Malignant neoplasm of vulva
C52.0	Malignant neoplasm of vagina
C53.0 – C53.9	Malignant neoplasm of endocervix, exocervix, overlapping sites of cervix uteri, unspecified cervix uteri
C54.0 – C54.8	Malignant neoplasm of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C56.1 – C57.9	Malignant neoplasm of ovary and other and unspecified female genital organs
C64.1 – C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1 – C65.9	Malignant neoplasm of unspecified renal pelvis
C70.0 – C70.9	Malignant neoplasm of meninges
C71.0 – C71.9	Malignant neoplasm of brain
C72.0	Malignant neoplasm of spinal cord
C72.9	Malignant neoplasm of central nervous system, unspecified
C78.00 – C78.02	Secondary malignant neoplasm of unspecified lung
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of meninges
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site
C83.30 – C83.89	Diffuse large B-cell lymphoma [Primary CNS Lymphoma]
C84.49	Peripheral T-cell lymphoma, not elsewhere classified, extranodal and solid organ sites
C85.89 – C85.99	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
D32.0 – D32.9	Benign neoplasm of meninges
D42.0 – D42.9	Neoplasm of uncertain behavior of meninges
D43.0 – D43.2	Neoplasm of uncertain behavior of brain, unspecified
D43.4	Neoplasm of uncertain behavior of spinal cord
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin
G93.6	Cerebral edema
I67.89 – I67.9	Other cerebrovascular disease
I78.0	Hereditary hemorrhagic telangiectasia
Q85.02 – Q85.03	Neurofibromatosis, type 2 and Schwannomatosis
Q85.83	Von Hippel-Lindau syndrome
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
T66.XXXA	Radiation sickness, unspecified, initial encounter
T66.XXXD	Radiation sickness, unspecified, subsequent encounter
T66.XXXS	Radiation sickness, unspecified, sequela

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage Products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline revised date for oncology indications.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

None.

RELATED GUIDELINES:

[Gemcitabine \(Gemzar\), 09-J0000-96](#)

[Irinotecan HCl \(Camptosar\) IV, 09-J0000-99](#)

[Tumor Markers, 05-86000-22](#)

[Vascular Endothelial Growth Factor Inhibitors of Ocular Neovascularization, 09-J1000-78](#)

[Verteporfin \(Visudyne™\) Injection, 09-J1000-72](#)

OTHER:

None applicable.

REFERENCES:

1. Aylmsys (bevacizumab-maly) [package insert]. Amneal Pharmaceuticals LLC. Bridgewater (NJ): April 2022.
2. Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. *Orphanet J Rare Dis*. 2019 Nov 14;14(1):256. doi: 10.1186/s13023-019-1239-6..
3. Avastin (bevacizumab) [package insert]. Genentech, Inc. South San Francisco (CA): September 2022.
4. Avzivi (bevacizumab-tnjn) [package insert]. Bio-Thera Solutions, Ltd. Guangzhou, Guangdong Province, China: December 2023.
5. Clinical Pharmacology [Internet]. Tampa (FL): Gold Standard, Inc.; 2025 [cited 2025 Sept 30]. Available from: <http://www.clinicalpharmacology.com/>.
6. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 Feb 29 - [cited 2015-06-13]. Available from: <http://clinicaltrials.gov/>.
7. DRUGDEX® System [Internet]. Greenwood Village (CO): Thomson Micromedex; Updated periodically [cited 2025 Sept 30].
8. Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, Leguy-Seguin V, Maillard H, Mohamed S, Decullier E, Roux A, Bernard L, Saurin JC, Saroul N, Faure F, Cartier C, Altwegg R, Laccourreye L, Oberti F, Beaudoin M, Dhelens C, Desvignes C, Azzopardi N, Paintaud G, Hermann R, Chinet T. Efficacy and safety of intravenous bevacizumab on severe bleeding associated

with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial. *J Intern Med.* 2023 Dec;294(6):761-774. doi: 10.1111/joim.13714. Epub 2023 Aug 23.

9. Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. *Ann Intern Med.* 2020 Dec 15;173(12):989-1001.
10. Furuse M, Nonoguchi N, Kuroiwa T et al. A prospective, multicenter, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. *Neurooncol Pract.* 2016; 3(4):272-280.
11. Jobevne (bevacizumab-nwgd) [package insert]. Biocon Biologics, Inc. Cambridge (MA): April 2025.
12. Mvasi (bevacizumab-awwb) [package insert]. Amgen, Inc. Thousand Oaks (CA): February 2023.
13. NCCN Drugs & Biologics Compendium [Internet]. Fort Washington (PA): National Comprehensive Cancer Network; 2025 [cited 2025 Jan 30]. Available from: http://www.nccn.org/professionals/drug_compendium/content/contents.asp/.
14. Orphan Drug Designations and Approval [Internet]. Silver Spring (MD): US Food and Drug Administration; 2025 [cited 2025 Jan 30]. Available from: <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm/>.
15. Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. *Am J Gastroenterol.* 2020 Jan;115(1):18-40
16. Vegzelma (bevacizumab-adcd) [package insert]. Celltrion, Inc.: February 2023.
17. Zirabev (bevacizumab-bvzr) [package insert]. Pfizer, Inc. New York (NY): August 2024.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Coverage Committee on 10/08/25.

GUIDELINE UPDATE INFORMATION:

11/15/06	New Medical Coverage Guideline.
07/15/07	Reviewed guideline: Maintain current coverage and limitations. Reformatted guideline, renamed putting generic first, and references.
07/15/08	Reviewed guideline with no change in coverage. Added statement regarding proper coding, added related guideline and updated references.
04/15/09	Review and revision of guideline; consisting of changing the name of the guideline, adding 5 new indications to the position statement, adding maximum dosing, updating references, and adding ICD-9 codes for cervical cancer.
10/01/09	Revision to guideline; consisting of updating maximum dosing description in Position statement, updating HCPCS coding and addition of 3 new diagnosis codes.
10/15/09	Revision to guideline; consisting of updating codes.
01/01/10	Annual HCPCS coding update: deleted HCPCS code Q2024.
01/15/10	Revision to guideline; consisting of updating coding.
04/15/10	Revision to guideline; consisting of updating coding.
08/01/10	Review and revision to guideline; consisting of updating ICD-9 coding, black box warning and references.

08/15/11	Review and revision to guideline; consisting of updating coding and references.
07/15/12	Revision to guideline; consisting of modifying dosage limitations.
08/15/12	Review and revision to guideline; consisting reformatting position statement, update precautions, coding, program exceptions and references.
12/15/12	Revision to guideline; consisting of removing ophthalmologic indications and referencing MCG# 09-J1000-78, Vascular Endothelial Growth Factor Inhibitors of Ocular Neovascularization.
04/15/13	Revision to guideline; consisting of adding new indication to position statement.
08/15/13	Review and revision to guideline; consisting of revising description section, revising and reformatting position statement, dosage/administration, and precautions sections; updating references, program exceptions and coding.
08/15/14	Review and revision to guideline; consisting of revising position statement, updating references, updating coding.
10/15/14	Revision to guideline; consisting of revising position statement.
11/15/14	Revision to guideline; consisting of position statement.
08/15/15	Review and revision to guidelines; consisting of position statement, references.
11/01/15	Revision: ICD-9 Codes deleted.
07/15/16	Review and revision to guideline; consisting of revising position statement; updating dosing, warnings, coding and references.
01/15/17	Revision to guideline; consisting of updating position statement, coding and references.
07/15/17	Review and revision to guideline; consisting of revising position statement, description, dosing, coding and references.
11/15/17	Revision to guideline; consisting of updating position statement and references.
07/15/18	Review and revision to guideline; consisting of updating position statement, coding, warnings and references.
08/15/18	Revision to guideline; consisting of updating position statement and references.
01/01/19	Revision: HCPCS code updates. Added Q5107.
07/15/19	Review and revision to guideline; consisting of updating position statement and references
10/01/19	Revision: Added HCPCS Q5118.
10/15/19	Review and revision to guideline; consisting of updating position statement, description, coding and references.
02/15/20	Revision to guideline consisting of updating position statement and references.
04/01/20	Review and revision to guideline consisting of updating the position statement.
05/15/20	Revision to guideline; consisting of updating the position statement and references.
08/15/20	Review and revision to guideline; consisting of updating the position statement, description, dosing and references.
07/15/21	Review and revision to guideline; consisting of updating the position statement and references.
11/15/21	Revision to guideline; consisting of updating the position statement, coding, and references.
06/15/22	Review and revision to guideline; consisting of updating the position statement, description, dosing, coding, and references.
10/01/22	Revision: Added HCPCS code C9142.
11/15/22	Review and revision to guideline; consisting of adding bevacizumab-adcd (Vegzelma) to the position statement, description, coding and dosing. Also included revisions to the position statement for central nervous system cancer, ovarian, and vulvar cancer.
01/01/22	Revision: Added HCPCS code Q5126 and deleted codes C9142 and J3590.
04/01/23	Revision: Added HCPCS code Q5129 and deleted code J9999.
08/15/23	Revision to guideline; consisting of updating the position statement for ampullary cancer, CNS cancer, hepatocellular carcinoma, mesothelioma, and ovarian cancer (NCCN). Update to coding and references.

02/15/24	Review and revision to guideline; consisting of updating the position statement to include Avzivi. Update to Ampullary cancer, CNS cancer, cervical cancer and uterine cancer (NCCN).
03/15/25	Review and revision to guideline; consisting of updating the position statement to include hereditary hemorrhagic telangiectasia and vaginal cancer. Revisions included for ampullary, cervical, CNS, colon, hepatic, kidney, ovarian, soft tissue sarcoma, uterine cancer. Updates to coding and references.
11/15/25	Review and revision to guideline; consisting of updating the position statement to include Jobevne. Update to cervical, CNS, hepatocellular and vulvar cancer and update to references.
01/01/26	Revision: For Jobevne, added HCPCS code Q5160 and removed code J9999.
06/01/26	Revision: Added Drug Waste Reduction statement to the Position Statement.